|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shalvata Mental Health Center |
|---|---|
| Collaborator: |
University of Haifa |
| Information provided by: | Shalvata Mental Health Center |
| ClinicalTrials.gov Identifier: | NCT00813436 |
Purpose
Empathy constitutes one prominent ability of social cognition, which represents the human capability of understanding mental state of the other, and responding in sympathetic way. Two sets of theoretical mechanisms were designed in order to explain how empathy is possible. Theory of Mind (ToM)and Simulation.People who suffer from schizophrenia frequently exhibit social dysfunction, preventing them of a normal integration in healthy human environments. Recently it had been discovered that impairment in empathy and a specific impairment in effective TOM are mostly associated with the social malfunctioning of people who suffer from schizophrenia. One of the biological substances most connected to social cognition is the neuromodulator Oxytocin. Among its known involvement in uterine contractions and lactating females, numerous recent studies have found an indispensable role for Oxytocin in various complex prosocial behaviors such as maternal behavior, attachment, partner preference and trust. In the proposed study, we plan to examine the influence of a single dose of intranasal Oxytocin on the two primary mechanisms of empathy, namely mentalizing (Theory of Mind) and Simulation, both in healthy people and in people who suffer from schizophrenia.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: Oxytocin (also: syntocinon, pitocin) Drug: Placebo |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | The Effect of Intranasal Administration of Oxytocin on Empathic Abilities of Healthy People and People Who Suffer From Schizophrenia. |
| Estimated Enrollment: | 100 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Oxytocin
|
Drug: Oxytocin (also: syntocinon, pitocin)
24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
Other Name: Novartis.
|
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo
saline liquid, intranasally administered
Other Name: Weleda
|
Social cognition encompasses a wide spectrum of abilities, enabling us to function properly in interpersonal interactions. Empathy constitutes one prominent ability of social cognition, which represents the human capability of understanding mental state of the other, and responding in sympathetic way (Leiberg & Anders, 2006). Two sets of theoretical mechanisms were designed in order to explain how empathy is possible. Theory of Mind (ToM) is usually regarded as a more cognitive mechanism of empathy, in which a theory we posses regarding the other enable us to infer his mental state. 'Simulation' processing is another different mechanism of empathy. In contrast to the ToM perspective, the simulation perspective asserts that understanding the other's state of mind is achieved by an inner representation of that mental state in our mind, thus simulating his mental state. Therefore, the simulation theory may be associated with more affective aspects of empathy.
Schizophrenia encompasses a wide spectrum of psychotic disorders, characterized by severe cognitive, emotional and behavioral impairments. People who suffer from schizophrenia frequently exhibit social dysfunction, preventing them of a normal integration in healthy human environments. Recently it had been discovered that impairment in empathy and a specific impairment in effective TOM are mostly associated with the social malfunctioning of people who suffer from schizophrenia.
One of the biological substances most connected to social cognition is the neuromodulator Oxytocin. Among its known involvement in uterine contractions and lactating females, numerous recent studies have found an indispensable role for Oxytocin in various complex prosocial behaviors such as maternal behavior, attachment, partner preference and trust. It was suggested that Oxytocin may mediate the beneficial affect of social support, and is found strongly involved in different kinds of attachment. In a recent study, Domes et al. (2006) found that an intranasal administration of a single dose of Oxytocin enhanced the ability to infer mental states as conveyed by the eyes region (RMET, Baron-Cohen et al. 1995). These findings suggest a mediating role for the ability to use social cues in order to infer the other mental states. In the proposed study, we plan to examine the influence of a single dose of intranasal Oxytocin on the two primary mechanisms of empathy, namely mentalizing (Theory of Mind) and Simulation, both in healthy people and in people who suffer from schizophrenia. Mentalizing will be assessed by a variation of a validated ToM task, which requires cognitive and affective mentalizing. Simulation will be tested in two different tasks: emotion recognition via a dynamic paradigm of facial expressions, and recognition of biological motion, which necessitates the identification of the emotion conveyed in a video clips of point light walkers. Both of these latter tasks have been associated with simulation processing.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria (for schizophrenic patients):
Inclusion Criteria (for healthy patients):
Exclusion Criteria (for schizophrenic patients):
Exclusion Criteria (for healthy patients):
Contacts and Locations| Contact: Meytal Fischer, Phd. Student | 972-9-7478644 | meytal.fischer@gmail.com |
| Contact: Simone Shamay-Tsoory, MA | 972-4-8288778 | sshamay@psy.haifa.ac.il |
| Israel | |
| Shalvata Mental Health Center | Recruiting |
| Hod Hasharon, Israel | |
| Contact: Yechiel Levkovitz, MD 972-9-7478697 ylevk@clalit.org.il | |
| Principal Investigator: Yechiel Levkovitz, MD | |
| Principal Investigator: | Yechiel Levkovitz, MD | Shalvata Mental Health Center |
| Study Director: | Simone Shamay-Tsoory, MA | University of Haifa |
More Information
| Responsible Party: | Dr. Yechiel Levkovitz, Shalvata Mental Health Center |
| ClinicalTrials.gov Identifier: | NCT00813436 History of Changes |
| Other Study ID Numbers: | 0007-07-SHA |
| Study First Received: | December 22, 2008 |
| Last Updated: | February 4, 2009 |
| Health Authority: | Israel: Ministry of Health |
|
ToM Theory of Mind Simulation |
Empathy Oxytocin Schizophrenia |
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Oxytocin Oxytocics |
Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |